3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Terminated
2
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
2
NET
1
Endocrine
1
Conditions
Carcinoma, Renal Cell
64
Neoplasm Metastasis
25
Kidney Neoplasms
21
Neoplasms
16
Breast Neoplasms
15
Carcinoma, Non-Small-Cell Lung
13
Urinary Bladder Neoplasms
12
Prostatic Neoplasms
10
Lung Neoplasms
8
Brain Neoplasms
8
Melanoma
7
Colorectal Neoplasms
7
Pancreatic Neoplasms
6
Ovarian Neoplasms
6
Neuroendocrine Tumors
6
Liver Neoplasms
6
Glioblastoma
6
Gastrointestinal Stromal Tumors
6
Carcinoma, Hepatocellular
6
Thyroid Neoplasms
5
Thymoma
5
Small Cell Lung Carcinoma
5
Recurrence
5
Multiple Myeloma
5
Esophageal Neoplasms
5
Carcinoma
5
Uveal Melanoma
4
Stomach Neoplasms
4
Sarcoma
4
Adenocarcinoma
4
Interventions
anlotinib
2
Sunitinib
2
Ocoxin
2
Carboplatin
2
Bevacizumab
2
sipuleucel-T
1
pembrolizumab
1
palbociclib
1
olaparib
1
niraparib
1
luprolide acetate gel depot
1
lenvatinib
1
ixabepilone
1
durvalumab
1
catumaxomab
1
Sorafenib
1
Radiotherapy, Intensity-Modulated
1
Paclitaxel
1
Leuprolide
1
Immunotherapy
1
Filgrastim
1
Cisplatin
1
Chemoradiotherapy
1
CP protocol
1
ALT-803
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2
×
Neoplasms, Glandular and Epithelial
×
Sunitinib
×
Clear all
NCT01215578
2015-04-30
NET
Assistance Publique - Hôpitaux de Paris
Phase 2
Terminated
33 enrolled
NCT01215565
2014-03-13
Fibrolam
Assistance Publique - Hôpitaux de Paris
Phase 2
Terminated
4 enrolled